drugset

drugset / Trial / NCT05170958

A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors

NCT05170958 ↗

Phase 1/2 Recruiting 396 enrolled Nanjing Leads Biolabs Co.,Ltd

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors

Timeline

Start: 2022-01-06
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LBL-024	Unknown	—	—

Indications